Scholarlink

<p>Antibodies that recognize insoluble antigens, such as amyloid fibrils associated with neurodegenerative disorders, are important for research, diagnostic and therapeutic applications. However, these types of antibodies are difficult to generate, typically require animal immunization and also commonly require humanization in the case of therapeutic applications. Here we report a methodology for generating high-quality, fully human, conformation-specific antibodies against amyloid fibrils using a published human nonimmune library, yeast-surface display and quantitative fluorescence-activated cell sorting. Notably, this approach enables the isolation of conformation-specific antibodies against tau fibrils (Alzheimer’s disease) and α-synuclein fibrils (Parkinson’s disease) with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to simplify the generation of conformation-specific antibodies against diverse protein aggregates and other insoluble antigens.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Facile generation of drug-like conformational antibodies specific for amyloid fibrils

  • 期刊论文

  • 发表日期：

    2025年4月29日

查看全文
  • Alec A. Desai,
  • Jennifer M. Zupancic,
  • Hanna Trzeciakiewicz,
  • Julia E. Gerson,
  • Kelly N. DuBois,
  • Mary E. Skinner,
  • Lisa M. Sharkey,
  • Nikki McArthur,
  • Sean P. Ferris,
  • Nemil N. Bhatt,
  • Emily K. Makowski,
  • Matthew D. Smith,
  • Hongwei Chen,
  • Jie Huang,
  • Cynthia Jerez,
  • Yun-Huai Kuo,
  • Ravi S. Kane,
  • Nicholas M. Kanaan,
  • Henry L. Paulson,
  • Peter M. Tessier

摘要

Antibodies that recognize insoluble antigens, such as amyloid fibrils associated with neurodegenerative disorders, are important for research, diagnostic and therapeutic applications. However, these types of antibodies are difficult to generate, typically require animal immunization and also commonly require humanization in the case of therapeutic applications. Here we report a methodology for generating high-quality, fully human, conformation-specific antibodies against amyloid fibrils using a published human nonimmune library, yeast-surface display and quantitative fluorescence-activated cell sorting. Notably, this approach enables the isolation of conformation-specific antibodies against tau fibrils (Alzheimer’s disease) and α-synuclein fibrils (Parkinson’s disease) with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to simplify the generation of conformation-specific antibodies against diverse protein aggregates and other insoluble antigens.